91 related articles for article (PubMed ID: 27939411)
1. Identification of novel mutations in Japanese ovarian clear cell carcinoma patients using optimized targeted NGS for clinical diagnosis.
Maru Y; Tanaka N; Ohira M; Itami M; Hippo Y; Nagase H
Gynecol Oncol; 2017 Feb; 144(2):377-383. PubMed ID: 27939411
[TBL] [Abstract][Full Text] [Related]
2. Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma.
Jones S; Wang TL; Shih IeM; Mao TL; Nakayama K; Roden R; Glas R; Slamon D; Diaz LA; Vogelstein B; Kinzler KW; Velculescu VE; Papadopoulos N
Science; 2010 Oct; 330(6001):228-31. PubMed ID: 20826764
[TBL] [Abstract][Full Text] [Related]
3. Prognostic impact of molecular profiles and molecular signatures in clear cell ovarian cancer.
Schnack TH; Oliveira DNP; Christiansen AP; Høgdall C; Høgdall E
Cancer Genet; 2023 Nov; 278-279():9-16. PubMed ID: 37567101
[TBL] [Abstract][Full Text] [Related]
4. Detection of Biallelic Loss of DNA Repair Genes in Formalin-Fixed, Paraffin-Embedded Tumor Samples Using a Novel Tumor-Only Sequencing Panel.
Glodzik D; Selenica P; Rogge RA; Silverman IM; Mandelker D; Harris S; Zhao J; Zinda M; Veloso A; Malani N; Riaz N; Koehler M; Daber RD; Johnson V; Rimkunas V; Reis-Filho JS
J Mol Diagn; 2023 May; 25(5):295-310. PubMed ID: 36944408
[TBL] [Abstract][Full Text] [Related]
5. The Potential Role of Complement System in the Progression of Ovarian Clear Cell Carcinoma Inferred from the Gene Ontology-Based Immunofunctionome Analysis.
Su KM; Lin TW; Liu LC; Yang YP; Wang ML; Tsai PH; Wang PH; Yu MH; Chang CM; Chang CC
Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32316695
[TBL] [Abstract][Full Text] [Related]
6. Impact of DNA integrity on the success rate of tissue-based next-generation sequencing: Lessons from nationwide cancer genome screening project SCRUM-Japan GI-SCREEN.
Kuwata T; Wakabayashi M; Hatanaka Y; Morii E; Oda Y; Taguchi K; Noguchi M; Ishikawa Y; Nakajima T; Sekine S; Nomura S; Okamoto W; Fujii S; Yoshino T;
Pathol Int; 2020 Dec; 70(12):932-942. PubMed ID: 33030786
[TBL] [Abstract][Full Text] [Related]
7. APOBEC3B stratifies ovarian clear cell carcinoma with distinct immunophenotype and prognosis.
Long X; Lu H; Cai MC; Zang J; Zhang Z; Wu J; Liu X; Cheng L; Cheng J; Cheung LWT; Shen Z; Zhou Y; Di W; Zhuang G; Yin X
Br J Cancer; 2023 Jun; 128(11):2054-2062. PubMed ID: 36997661
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Somatic Mutation Profiles Between Formalin-Fixed Paraffin Embedded Tissues and Plasma Cell-Free DNA from Ovarian Cancer Patients Before and After Surgery.
Jagelkova M; Zelinova K; Laucekova Z; Bobrovska M; Dankova Z; Grendar M; Dokus K
Biores Open Access; 2020; 9(1):73-79. PubMed ID: 32219013
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive Molecular Profiling and Clinicopathological Characteristics of Gastric-Type Mucinous Carcinoma of the Uterine Cervix in Japanese Women.
Nasu H; Nishio S; Park J; Tasaki K; Terada A; Tsuda N; Kawano K; Kojiro-Sanada S; Akiba J; Ushijima K
Kurume Med J; 2024 May; 69(3.4):237-249. PubMed ID: 38369337
[TBL] [Abstract][Full Text] [Related]
10. Primary urethral clear-cell adenocarcinoma: comprehensive analysis by surgical pathology, cytopathology, and next-generation sequencing.
Mehra R; Vats P; Kalyana-Sundaram S; Udager AM; Roh M; Alva A; Pan J; Lonigro RJ; Siddiqui J; Weizer A; Lee C; Cao X; Wu YM; Robinson DR; Dhanasekaran SM; Chinnaiyan AM
Am J Pathol; 2014 Mar; 184(3):584-91. PubMed ID: 24389164
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive characterization of genomic features and clinical outcomes following targeted therapy and secondary cytoreductive surgery in OCCC: a single center experience.
Wijaya ST; Ngoi NY; Loh JW; Tan TZ; Lim D; Khan IS; Thian YL; Lai A; Ang BW; Tong P; Ng J; Low JJ; Ilancheran A; Lim SE; Lim YW; Tan DS
J Gynecol Oncol; 2024 Mar; ():. PubMed ID: 38606821
[TBL] [Abstract][Full Text] [Related]
12. Genomic Sub-Classification of Ovarian Clear Cell Carcinoma Revealed by Distinct Mutational Signatures.
Oliveira DVNP; Schnack TH; Poulsen TS; Christiansen AP; Høgdall CK; Høgdall EV
Cancers (Basel); 2021 Oct; 13(20):. PubMed ID: 34680390
[TBL] [Abstract][Full Text] [Related]
13. Prioritizing Clinically Significant Lung Cancer Somatic Mutations for Targeted Therapy Through Efficient NGS Data Filtering System.
Wang J; Li H; Liu H
AMIA Jt Summits Transl Sci Proc; 2024; 2024():305-313. PubMed ID: 38827108
[TBL] [Abstract][Full Text] [Related]
14. Dynamics of clonal evolution in myelodysplastic syndromes.
Makishima H; Yoshizato T; Yoshida K; Sekeres MA; Radivoyevitch T; Suzuki H; Przychodzen B; Nagata Y; Meggendorfer M; Sanada M; Okuno Y; Hirsch C; Kuzmanovic T; Sato Y; Sato-Otsubo A; LaFramboise T; Hosono N; Shiraishi Y; Chiba K; Haferlach C; Kern W; Tanaka H; Shiozawa Y; Gómez-Seguí I; Husseinzadeh HD; Thota S; Guinta KM; Dienes B; Nakamaki T; Miyawaki S; Saunthararajah Y; Chiba S; Miyano S; Shih LY; Haferlach T; Ogawa S; Maciejewski JP
Nat Genet; 2017 Feb; 49(2):204-212. PubMed ID: 27992414
[TBL] [Abstract][Full Text] [Related]
15. Identification of somatic genetic alterations in ovarian clear cell carcinoma with next generation sequencing.
Shibuya Y; Tokunaga H; Saito S; Shimokawa K; Katsuoka F; Bin L; Kojima K; Nagasaki M; Yamamoto M; Yaegashi N; Yasuda J
Genes Chromosomes Cancer; 2018 Feb; 57(2):51-60. PubMed ID: 29044863
[TBL] [Abstract][Full Text] [Related]
16. Prognosis of patients with BRCA1-associated ovarian carcinomas depends on TP53 accumulation status in tumor cells.
Rzepecka IK; Szafron LM; Stys A; Felisiak-Golabek A; Podgorska A; Timorek A; Sobiczewski P; Pienkowska-Grela B; El-Bahrawy M; Kupryjanczyk J
Gynecol Oncol; 2017 Feb; 144(2):369-376. PubMed ID: 27939982
[TBL] [Abstract][Full Text] [Related]
17. Delivering widespread BRCA testing and PARP inhibition to patients with ovarian cancer.
George A; Kaye S; Banerjee S
Nat Rev Clin Oncol; 2017 May; 14(5):284-296. PubMed ID: 27958297
[TBL] [Abstract][Full Text] [Related]
18. The mTORC1/2 Inhibitor AZD8055 Strengthens the Efficiency of the MEK Inhibitor Trametinib to Reduce the Mcl-1/[Bim and Puma] ratio and to Sensitize Ovarian Carcinoma Cells to ABT-737.
Pétigny-Lechartier C; Duboc C; Jebahi A; Louis MH; Abeilard E; Denoyelle C; Gauduchon P; Poulain L; Villedieu M
Mol Cancer Ther; 2017 Jan; 16(1):102-115. PubMed ID: 27980105
[TBL] [Abstract][Full Text] [Related]
19. Exome Sequencing Landscape Analysis in Ovarian Clear Cell Carcinoma Shed Light on Key Chromosomal Regions and Mutation Gene Networks.
Murakami R; Matsumura N; Brown JB; Higasa K; Tsutsumi T; Kamada M; Abou-Taleb H; Hosoe Y; Kitamura S; Yamaguchi K; Abiko K; Hamanishi J; Baba T; Koshiyama M; Okuno Y; Yamada R; Matsuda F; Konishi I; Mandai M
Am J Pathol; 2017 Oct; 187(10):2246-2258. PubMed ID: 28888422
[TBL] [Abstract][Full Text] [Related]
20. PIK3CA mutations as prognostic factor in squamous cell lung carcinoma.
McGowan M; Hoven AS; Lund-Iversen M; Solberg S; Helland Å; Hirsch FR; Brustugun OT
Lung Cancer; 2017 Jan; 103():52-57. PubMed ID: 28024696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
